Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Clene Inc.

Market Cap 70.66M 61.03M 56.24M 52.64M 98.66M 6.72B 100M 664M 259M 3.27B 265M 260M 11.32B P/E Ratio 2026 *
-3.1x
P/E Ratio 2027 * -3.76x
Enterprise Value 57.26M 49.46M 45.58M 42.66M 79.95M 5.44B 81.19M 538M 210M 2.65B 215M 210M 9.17B EV / Sales 2026 *
276x
EV / Sales 2027 * 2.08x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day+5.61%
1 week+7.16%
Current month-10.98%
1 month-10.15%
3 months-1.35%
6 months-13.74%
Current year-0.51%
1 week 5.25
Extreme 5.25
5.89
1 month 5.25
Extreme 5.25
7.37
Current year 3.88
Extreme 3.88
8.67
1 year 3.25
Extreme 3.25
13.5
3 years 2.28
Extreme 2.2801
21.8
5 years 2.28
Extreme 2.2801
356.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
05-21Free

Director

3,728 0.0317%
05-21
MatlinPatterson Global Advisers LLC
FreeCompany 5,159 0.0438%
05-21Free

Director

3,658 0.0311%
Change 5-day change 1-year change 3-year change Capi.($)
+5.61%+7.16%+43.14%-73.21% 70.66M
+1.03%+7.52%+54.74%+114.98% 55.58B
+2.72%+3.06%+53.28%+47.85% 43.47B
+1.12%+2.79%-13.71%-17.53% 22.64B
+1.17%+3.85%+1.00%+401.79% 20.96B
+3.81%-4.13%+16.62%-30.70% 15.79B
+0.15%+2.24%+9.06%-39.50% 15.3B
-0.69%+0.82%+27.17%+178.31% 13.45B
+5.27%+6.41%+21.05% - 11.74B
+1.61%+1.17%+90.79%+212.97% 10.96B
Average +2.18%-0.27%+30.31%+88.33% 21B
Weighted average by Cap. +1.71%+1.60%+33.73%+101.58%

Financials

2026 *2027 *
Net sales 207K 179K 165K 155K 290K 19.71M 294K 1.95M 760K 9.6M 778K 762K 33.22M 23.64M 20.42M 18.82M 17.61M 33.01M 2.25B 33.52M 222M 86.63M 1.09B 88.74M 86.85M 3.79B
Net income -25.09M -21.67M -19.97M -18.69M -35.04M -2.39B -35.58M -236M -91.95M -1.16B -94.18M -92.17M -4.02B -27.55M -23.79M -21.93M -20.52M -38.46M -2.62B -39.06M -259M -101M -1.27B -103M -101M -4.41B
Net Debt -13.4M -11.57M -10.67M -9.98M -18.71M -1.27B -19M -126M -49.1M -620M -50.29M -49.22M -2.15B -21.4M -18.48M -17.03M -15.94M -29.88M -2.03B -30.34M -201M -78.41M -990M -80.31M -78.6M -3.43B
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
78
Date Price Change Volume
13/06/26 5.840 $ +5.61% 78,275
11/06/26 5.530 $ +0.55% 72,416
10/06/26 5.500 $ -1.26% 125,451
09/06/26 5.570 $ +4.50% 103,582
08/06/26 5.330 $ -2.20% 87,009
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.530USD
Average target price
32.20USD
Spread / Average Target
+482.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!